Dianthus Therapeutics Inc. (NASDAQ: DNTH) announced an early go decision for its Phase 3 CAPTIVATE trial of claseprubart in chronic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE